Clin Immunol:HBV通过NF-Kb途径参与肝病的进展

2021-07-13 MedSci原创 MedSci原创

髓样细胞-1(TREM-1)信号上表达的触发受体与炎症通路的持续放大有关。然而,HBV是否以及如何调节单核细胞上TREM-1的表达参与肝病进展尚不清楚。为此,研究人员进行了探究,研究结果已发表于Cli

髓样细胞-1(TREM-1)信号上表达的触发受体与炎症通路的持续放大有关。然而,HBV是否以及如何调节单核细胞上TREM-1的表达参与肝病进展尚不清楚。为此,研究人员进行了探究,研究结果已发表于Clin Immunol。

结果显示,与慢性感染组和健康对照组相比,HBV相关肝硬化组单核细胞亚群上TREM-1的表达显著增加。HBsAg和HBeAg可通过NF-KB通路上调单核细胞上的 TREM-1,并至少持续 72 h。单核细胞上增加的 TREM-1 可能与高水平的炎性细胞因子(TNF-a、IL-1β 和 IL-6)和 LX-2 细胞的活化有关。生物信息学分析表明,TREM-1的高表达与肝细胞癌(HCC)的不良预后有关。

综上,该研究结果表明,TREM-1 的水平可能有助于预测 HBV 感染的肝脏疾病的进展和治疗目标,以防止纤维化进展。

 

原始出处:

 

Xiaojuan Wu, et al., HBV upregulated triggering receptor expressed on myeloid cells-1 (TREM-1) expression on monocytes participated in disease progression through NF-Kb pathway. Clin Immunol. 2021 Feb;223:108650. doi: 10.1016/j.clim.2020.108650.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836704, encodeId=f3261836e04a2, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Thu Jul 29 04:29:56 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536962, encodeId=ce461536962a7, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Wed Jul 14 16:29:56 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998971, encodeId=afe29989e192, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2a131713674, createdName=1deacbaem62(暂无匿称), createdTime=Tue Jul 13 06:34:54 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
    2021-07-29 klivis
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836704, encodeId=f3261836e04a2, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Thu Jul 29 04:29:56 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536962, encodeId=ce461536962a7, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Wed Jul 14 16:29:56 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998971, encodeId=afe29989e192, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2a131713674, createdName=1deacbaem62(暂无匿称), createdTime=Tue Jul 13 06:34:54 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
    2021-07-14 jichang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836704, encodeId=f3261836e04a2, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Thu Jul 29 04:29:56 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536962, encodeId=ce461536962a7, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Wed Jul 14 16:29:56 CST 2021, time=2021-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998971, encodeId=afe29989e192, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2a131713674, createdName=1deacbaem62(暂无匿称), createdTime=Tue Jul 13 06:34:54 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
    2021-07-13 1deacbaem62(暂无匿称)

    学习

    0

相关资讯

JVH:HBV pgRNA能够预测NAs抗病毒治疗慢性乙型肝炎患者的长期预后

研究共纳入了98名接受了7年抗病毒治疗的初治慢性乙型肝炎患者。使用实时定量PCR及特异性引物分析了患者血清中HBV pgRNA的水平。

J Hepatology:慢性HBV合并感染HCV患者直接作用抗病毒治疗后的乙肝相关结局分析

乙型肝炎病毒(HBV)感染的结果,包括乙型肝炎表面抗原(HBsAg)阳性和乙型肝炎病毒的再激活,在接受直接作用抗病毒药物(DAA)的丙型肝炎病毒(HCV)合并感染的患者中这样的结局尚不清楚。因此,本项研究旨在相关研究。

J Hepatology:干扰素诱导的MX2是乙型肝炎病毒复制的限制因素

I型干扰素(IFN)在内的细胞因子的可以治愈乙型肝炎病毒(HBV)感染的肝细胞对于解决急性和慢性感染至关重要。但是,IFN会影响数百种基因,与HBV抑制最相关的那些基因在很大程度上仍然未知。其中包括大型Mx GTPases。人类MX1(或MxA)对许多RNA病毒具有活性,而最近发现MX2(或MxB)限制了人类免疫缺陷病毒,丙型肝炎病毒和疱疹病毒。在这里,研究人员研究了MX2的抗乙肝病毒的能力。

Gastroenterology:核酸聚合物REP 2139/REP2165、替诺福韦联合干扰素可提高HBV治疗效果

核酸聚合物REP 2139或REP2165耐受性良好,与替诺福韦酯和聚乙二醇干扰素联合治疗可显著提高乙肝治疗效果

Lancet Gastroen Hepatol:替诺福韦艾拉酚胺治疗HBV感染

与替诺福韦二吡呋酯相比,替诺福韦艾拉酚胺的疗效相当,且更为安全

GUT:HBV整合促进肝细胞癌局部及远距离致癌驱动因子的改变

这项研究强调乙型肝炎病毒(HBC)相关的肝细胞癌(HCC)可通过不同的机制促进。肝组织中HBV整合的深入表征揭示了与肝癌发生有关的新HBV相关驱动程序机制。